X
<

Columbia Sportswear Rises in 2Q17: Top-Line, Bottom-Line Beats

PART:
1 2 3 4
Part 4
Columbia Sportswear Rises in 2Q17: Top-Line, Bottom-Line Beats PART 4 OF 4

No Ratings Changes after Columbia Sportswear’s 2Q17 Results

Columbia Sportswear’s ratings

Columbia Sportswear’s (COLM) analyst ratings remained unchanged after it reported its 2Q17 results. The company is currently covered by 19 Wall Street analysts, who have together rated the stock a 2.3 on a scale of 1.0 (“strong buy”) to 5.0 (“sell”).

Looking at the recommendations, 42.0% of Wall Street analysts, including Wedbush and Guggenheim, are recommending a “buy” for COLM stock. Stifel and Canaccord Genuity are among the 53.0% of brokers who are recommending a “hold” for COLM stock.

No Ratings Changes after Columbia Sportswear’s 2Q17 Results

Interested in COLM? Don't miss the next report.

Receive e-mail alerts for new research on COLM

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

How are competitors rated?

Among the major sportswear players, Nike (NKE) is the best-rated stock. The company has a 2.2 rating with 61.0% “buy” and 36.0% “hold” recommendations.

Lululemon Athletica (LULU) is rated a 2.5 with 43.0% “buy” and 49.0% “hold” recommendations.

Under Armour (UAA) has the highest percentage of “sell” ratings at ~21.0%. That’s higher than COLM (5.0%), LULU (9.0%), and Nike (3.0%). The company is rated 2.9 with 21.0% “buy” and 58.0% “hold” recommendations.

Target price

COLM is currently trading at $62, which is ~2.5% below its 52-week high. Wall Street expects the stock to rise another 2.0% to $63.24 over the next 12 months.

The company has a better upside than Lululemon Athletica, whose stock is predicted to fall 1.0%. UAA and NKE, however, have 11.0% and 6.0% upsides, respectively.

ETF investors seeking to add exposure to COLM can consider the iShares Morningstar Small-Cap Growth (JKK), which invests ~0.30% of its portfolio in COLM.

X

Please select a profession that best describes you: